Key Takeaways - CMS launches Drug Acquisition Cost Survey beginning Jan. 1, 2026. OPPS hospitals must submit NDC-level pricing data for ...

Senator calls on Congress to increase oversight of the 340B Drug Pricing Program by requiring participating providers to complete annual reports on program savings and revenues. If your health system ...

On October 26, 2023, the Health Resources and Services Administration (HRSA) issued a Notice to “inform and remind” 340B Program covered entities that to be considered eligible for the 340B program, ...

The American Hospital Association, a Maine hospital group and four nonprofit systems are seeking a temporary restraining ...

The drug industry and hospitals have been butting heads over the future of a federal drug pricing program for more than a year, according to The Washington Post. Federal regulators may finalize ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

Under the 340B program, eligible hospitals buy drugs at a discounted price in order to offset the cost of treating low income ...

Despite the rancor, there are many bipartisan opportunities for the divided 118 th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug ...

Hospitals are up in arms over new guidance issued by the Health Resources and Services Administration on Thursday that could restrict the eligibility of their outpatient clinics for drug discounts in ...

The 340B drug pricing program is complicated. A clinic leader and a hospital said that’s making it easy for there to be misunderstandings about if the savings are being passed onto the patient.

At Care Free Medical, we provide medical, dental, optometry and behavioral health services for underinsured and uninsured adults and children from across Metro Lansing. It’s difficult work in a ...

In 1992, Congress established the 340B Program, which requires drug manufacturers, as a condition of participation in Medicare and Medicaid, to sell their drugs to 340B covered entities, such as ...